Imidazole derivatives
AssigneeHoffmann-La Roche Inc.
InventorsAlexander Alanine, Bernd Buettelmann, Marie-Paule Heitz Neidhart, Georg Jaeschke, Emmanuel Pinard, Rene Wyler
Life of this patent
Estimating the term…
Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsAlexander Alanine, Bernd Buettelmann, Marie-Paule Heitz Neidhart, Georg Jaeschke, Emmanuel Pinard, Rene Wyler
Estimating the term…
Novel imidazole derivatives are disclosed. These compounds have a good affinity to the NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation. These compounds are useful in the control or treatment of diseases mediated by this receptor.
A compound of formula
The compound of formula Ie in accordance with claim 15, wherein R1 and R2 are each independently selected from lower alkyl, halogen and CF3;
The compound of formula Ie in accordance with claim 16, which is selected from the group consisting of
The compound of formula If in accordance with claim 18, wherein and R1 and R2 are each independently selected from halogen;
The compound of formula If in accordance with claim 19, which is 4-(3,4-dichloro-phenyl)-2-(2-methyl-imidazol-1-yl-methyl)-pyridine.
The compound of formula Ig in accordance with claim 21, wherein R1 and R2 are each independently selected from halogen;
The compound of formula Ig in accordance with claim 22, which is 2-(3,4-dichloro-phenyl)-4-(2-methyl-imidazol-1-yl-methyl)-pyridine.
A compound of formula
A compound selected from the group
A pharmaceutical composition comprising one or more compounds of formula I or a pharmaceutically acceptable salt thereof, and an inert carrier.
A method of making a compound of formula I comprising:
A method of making a compound of formula I comprising:
A method of making a compound of formula I comprising:
The method of claim 35 wherein the NMDA-receptor disease is acute neurodegeneration caused by stroke or brain trauma.
The method of claim 35 wherein the NMDA-receptor disease is chronic neurodegeneration caused by Alzheimer's disease, Parkinson's disease, Huntington's disease, or ALS (amyotrophic lateral sclerosis).
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Backward citations are indexed for grants only.
Having two double bonds between ring members or between ring members and non-ring members: with substituted hydrocarbon radicals attached to ring…
Drugs for disorders of the nervous system
Drugs for disorders of the nervous system: centrally acting analgesics, e.g. opioids
Drugs for disorders of the nervous system: for treating abnormal movements, e.g. chorea, dyskinesia
Term end not estimated
The present invention relates to compounds of formula 1
having valuable CNS, learning and memory forming pharmacological properties.
Under pathological conditions of acute and chronic forms of neurodegeneration overactivation of NMDA receptors is a key event for triggering neuronal cell death. NMDA receptors are composed of members from two subunit families, namely NR-1 (8 different splice variants) and NR-2 (A to D) originating from different genes. Members from the two subunit families show a distinct distribution in different brain areas. Heteromeric combinations of NR-1 members with different NR-2 subunits result in NMDA receptors displaying different pharmaceutical properties. Therapeutic indications for NMDA NR-2B receptor subtype specific blockers include acute forms of neurodegeneration caused, e.g., by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis) and neurodegeneration associated with bacterial or viral infections, and, in addition, depression and chronic and acute pain.
Sodium hydride (0.44 g of a 55% dispersion in mineral oil, 10 mmol) was slowly added to a solution of 2-propylimidazole (0.55 g, 5 mmol) in DMF. After 30 min at 20° C. the mixture was cooled in an ice bath and 4-chloromethyl-1-(3,4-dichloro-phenyl)-1H-imidazole (1.0 g, 4 mmol) was added in one portion. The resulting mixture was stirred for 30 min at 20° C. After evaporation of the solvent, the residue was dissolved in AcOEt, washed with H2O, dried (Na2SO4) and chromatographed [silica, elution with gradient CH2Cl2 to 50% (CH2Cl2/MeOH/aq. NH4OH=90:10:1)]. The free base of the title compound was obtained as a brownish oil (1.12 g, 84%). After treatment with a solution of HCl in MeOH followed by addition of Et2O the title compound was isolated as a white crystalline material. Mp. 241-243° C. (MeOH/Et2O), MS: m/e=334(M+).
Examples 2 to 9 were prepared according to the general procedure described in example 1.
Reaction of 2-methylimidazole with sodium hydride followed by treatment with 4-chloromethyl-1-(3,4-dichloro-phenyl)-1H-imidazole led after extractive workup and chromatography to the free base of the title compound, which was converted into its white hydrochloride salt. Mp. >250° C. (MeOH/Et2O), MS: m/e=306(M+).